Skip to main content

Table 3 Quality-adjusted survival (QAS) estimated from a sample through the standard gamble (SG) method

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

 

Goserelin

Chemotherapy

Life expectancy of patient population

432 ± 23

401 ± 17

Life expectancy of reference population

474 ± 1

467 ± 1

SG of patient population

0.81

0.78

SG of reference population

1

1

QAS of patient population

341 ± 31

336 ± 39

QAS of reference population

476 ± 1

468 ± 1

QAS lost

135

132